SoftBank-backed Vir Biotechnology raises $143 million in U.S. IPO

Vir Biotechnologypriced its initial public offering (IPO) at $20 a share on Thursday, at the bottom end of expectations, a fresh blow for SoftBank Group Corp'sVision Fund, owner of 21% in the infectious disease researcher.